NasdaqCM:ATOS

Stock Analysis Report

Executive Summary

Atossa Genetics Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States.

Snowflake

Fundamentals

Excellent balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Atossa Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.7%

ATOS

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

18.0%

ATOS

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: ATOS exceeded the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: ATOS exceeded the US Market which returned 7.3% over the past year.


Shareholder returns

ATOSIndustryMarket
7 Day4.7%2.0%1.8%
30 Day-11.9%-1.8%-0.7%
90 Day-13.2%-0.5%0.06%
1 Year18.0%18.0%14.2%13.3%9.7%7.3%
3 Year-91.8%-91.8%70.5%65.3%46.3%36.9%
5 Year-99.1%-99.1%127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Atossa Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atossa Genetics undervalued compared to its fair value and its price relative to the market?

0.96x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ATOS's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ATOS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATOS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ATOS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ATOS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATOS is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Atossa Genetics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

56.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: ATOS is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: ATOS's loss is forecast to worsen by 0% next year.

Revenue vs Market: Insufficient data to determine if ATOS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ATOS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if ATOS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Atossa Genetics performed over the past 5 years?

-13.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ATOS is unprofitable, and losses have increased over the past 5 years at a rate of -13.6% per year.

Accelerating Growth: Unable to compare ATOS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATOS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: ATOS has a negative Return on Equity (-95.28%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ATOS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ATOS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Atossa Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: ATOS's short term assets ($18.4M) exceeds its short term liabilities ($1.0M)

Long Term Liabilities: ATOS's short term assets (18.4M) exceeds its long term liabilities (24.0K)


Debt to Equity History and Analysis

Debt Level: ATOS is debt free.

Reducing Debt: ATOS has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ATOS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ATOS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATOS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ATOS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Atossa Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ATOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ATOS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ATOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATOS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Atossa Genetics's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average management tenure


CEO

Steve Quay (68yo)

10.5yrs

Tenure

US$1,881,344

Compensation

Dr. Steven C. Quay, also known as Steve, M.D., Ph.D., FCAP has been the Chief Executive Officer and President of Atossa Genetics, Inc. since April 30, 2009 and served as its Chief Financial Officer since A ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Steve's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.8yrs

Average Tenure

Experienced Management: ATOS's management team is considered experienced (4.8 years average tenure).


Board Age and Tenure

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: ATOS's board of directors are considered experienced (5.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Steve Quay (68yo)

    Chairman

    • Tenure: 10.5yrs
    • Compensation: US$1.88m
  • Kyle Guse (55yo)

    CFO, General Counsel & Secretary

    • Tenure: 6.8yrs
    • Compensation: US$905.33k
  • Janet Rea

    Senior Vice President of Regulatory

    • Tenure: 1.8yrs
  • Jack Cuzick

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs

Board Members

  • Rich Steinhart (62yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$172.64k
  • Greg Weaver (63yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$172.64k
  • Steve Quay (68yo)

    Chairman

    • Tenure: 10.5yrs
    • Compensation: US$1.88m
  • Larry Remmel (67yo)

    Independent Director

    • Tenure: 7.7yrs
    • Compensation: US$92.64k
  • Carl Novina

    Scientific Advisor

    • Tenure: 1.8yrs
  • Shu-Chih Chen (57yo)

    Director

    • Tenure: 10.5yrs
    • Compensation: US$142.64k
  • Stephen Galli (72yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$167.64k
  • Bob Miglani

    Member of Strategic Advisory Board

    • Tenure: 1.4yrs
  • Jack Cuzick

    Member of Scientific Advisory Board

    • Tenure: 2.8yrs
  • Per Hall

    Scientific Advisor

    • Tenure: 1.6yrs

Company Information

Atossa Genetics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atossa Genetics Inc.
  • Ticker: ATOS
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.159m
  • Shares outstanding: 9.13m
  • Website: https://www.atossagenetics.com

Number of Employees


Location

  • Atossa Genetics Inc.
  • 107 Spring Street
  • Seattle
  • Washington
  • 98104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ATOSNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2012
YAG2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2012
YAG2BST (Boerse-Stuttgart)YesCommon StockDEEURNov 2012

Biography

Atossa Genetics Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, con ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:07
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.